News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pfizer Inc. (PFE) Statement On Status Of Bextra



10/19/2005 5:10:20 PM

NEW YORK, May 10 /PRNewswire-FirstCall/ -- In response to media inquiries, Pfizer today issued the following statement:

As previously communicated, Pfizer has suspended sales of Bextra (valdecoxib) pending further discussions with the U.S. Food and Drug Administration (FDA).

Pfizer continues to believe that Bextra could be an important treatment option for certain patient populations. In the future, the company plans to discuss options with the FDA under which Bextra might be made available to those patients.

Photo: A free corporate logo to accompany this story is availableimmediately via Wieck Photo Database to any media with telephoto receiver orelectronic darkroom, PC or Macintosh, that can accept overhead transmissions.To retrieve a logo, please call 972-392-0888. Pfizer Inc

CONTACT: Mariann Caprino, +1-212-733-4554, for Pfizer Inc

Company News On-Call: Pfizer's press releases are available through PRNewswire's Company News On-Call service on PRN's Web Site. Visithttp://www.prnewswire.com/comp/688250.html

Company News On-Call: http://www.prnewswire.com/comp/688250.html


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES